Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Anticoagulants | 122 | 2024 | 4812 | 11.290 |
Why?
|
Venous Thromboembolism | 72 | 2024 | 1866 | 9.460 |
Why?
|
Thrombosis | 52 | 2024 | 2942 | 8.740 |
Why?
|
Hemorrhage | 47 | 2024 | 3424 | 4.680 |
Why?
|
Heparin | 21 | 2024 | 1634 | 4.350 |
Why?
|
Thrombophilia | 12 | 2021 | 305 | 4.160 |
Why?
|
Warfarin | 18 | 2024 | 1483 | 4.040 |
Why?
|
Heart-Assist Devices | 23 | 2024 | 1287 | 3.920 |
Why?
|
Blood Coagulation Factors | 8 | 2024 | 365 | 3.910 |
Why?
|
Thromboembolism | 18 | 2024 | 995 | 3.730 |
Why?
|
Factor Xa | 8 | 2024 | 167 | 3.270 |
Why?
|
Thrombocytopenia | 12 | 2023 | 1182 | 2.990 |
Why?
|
International Normalized Ratio | 11 | 2024 | 382 | 2.760 |
Why?
|
Blood Coagulation | 22 | 2024 | 1154 | 2.720 |
Why?
|
Blood Coagulation Disorders | 13 | 2024 | 350 | 2.710 |
Why?
|
Venous Thrombosis | 13 | 2024 | 1303 | 2.650 |
Why?
|
Fibrinolytic Agents | 16 | 2024 | 2084 | 2.460 |
Why?
|
Pregnancy Complications, Hematologic | 10 | 2021 | 180 | 2.450 |
Why?
|
Pyridones | 17 | 2024 | 809 | 2.370 |
Why?
|
Neoplasms | 44 | 2024 | 22173 | 2.330 |
Why?
|
Heparin, Low-Molecular-Weight | 13 | 2024 | 344 | 2.030 |
Why?
|
Vitamin K | 7 | 2024 | 318 | 2.030 |
Why?
|
Nomograms | 5 | 2024 | 230 | 2.000 |
Why?
|
Recombinant Proteins | 12 | 2024 | 6534 | 1.670 |
Why?
|
Blood Coagulation Tests | 10 | 2021 | 271 | 1.660 |
Why?
|
Pyrazoles | 16 | 2024 | 2009 | 1.650 |
Why?
|
Extracorporeal Membrane Oxygenation | 7 | 2024 | 1462 | 1.620 |
Why?
|
Antidotes | 5 | 2019 | 138 | 1.570 |
Why?
|
Pulmonary Embolism | 16 | 2022 | 2567 | 1.500 |
Why?
|
Dalteparin | 8 | 2024 | 44 | 1.430 |
Why?
|
Purpura, Thrombocytopenic, Idiopathic | 3 | 2023 | 242 | 1.430 |
Why?
|
Fibrin Fibrinogen Degradation Products | 13 | 2022 | 422 | 1.390 |
Why?
|
von Willebrand Diseases | 6 | 2024 | 132 | 1.380 |
Why?
|
Administration, Oral | 26 | 2024 | 4021 | 1.360 |
Why?
|
Premedication | 3 | 2019 | 246 | 1.350 |
Why?
|
Disseminated Intravascular Coagulation | 8 | 2024 | 186 | 1.320 |
Why?
|
Hirudins | 4 | 2017 | 179 | 1.280 |
Why?
|
Humans | 324 | 2024 | 761572 | 1.230 |
Why?
|
Hemostasis | 8 | 2024 | 467 | 1.150 |
Why?
|
Antithrombins | 9 | 2023 | 294 | 1.140 |
Why?
|
Coronavirus Infections | 10 | 2020 | 3086 | 1.130 |
Why?
|
Pneumonia, Viral | 10 | 2020 | 3206 | 1.120 |
Why?
|
Hodgkin Disease | 20 | 2017 | 1378 | 1.050 |
Why?
|
Hemostatics | 5 | 2023 | 241 | 1.020 |
Why?
|
Platelet Aggregation Inhibitors | 13 | 2024 | 2751 | 1.020 |
Why?
|
Partial Thromboplastin Time | 8 | 2024 | 204 | 1.010 |
Why?
|
Hematologic Neoplasms | 5 | 2021 | 1896 | 0.990 |
Why?
|
Myeloproliferative Disorders | 2 | 2021 | 613 | 0.970 |
Why?
|
Atrial Fibrillation | 10 | 2024 | 5127 | 0.930 |
Why?
|
Recurrence | 21 | 2024 | 8466 | 0.920 |
Why?
|
Factor XI Deficiency | 2 | 2021 | 16 | 0.870 |
Why?
|
Drug Monitoring | 4 | 2019 | 962 | 0.870 |
Why?
|
Vaccines | 2 | 2022 | 844 | 0.860 |
Why?
|
Atrial Flutter | 2 | 2024 | 252 | 0.810 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 17 | 2015 | 1405 | 0.800 |
Why?
|
Blood Component Transfusion | 2 | 2019 | 142 | 0.790 |
Why?
|
Aspirin | 8 | 2023 | 3133 | 0.780 |
Why?
|
Peptide Fragments | 4 | 2017 | 5112 | 0.740 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 5 | 2024 | 1551 | 0.720 |
Why?
|
Hematology | 2 | 2023 | 243 | 0.700 |
Why?
|
Vasculitis | 2 | 2021 | 521 | 0.690 |
Why?
|
Hemophilia B | 2 | 2023 | 84 | 0.690 |
Why?
|
Pandemics | 15 | 2023 | 8656 | 0.680 |
Why?
|
Red-Cell Aplasia, Pure | 2 | 2018 | 27 | 0.680 |
Why?
|
Muscular Diseases | 1 | 2024 | 553 | 0.680 |
Why?
|
Hemophilia A | 3 | 2023 | 360 | 0.680 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 35 | 2024 | 11742 | 0.660 |
Why?
|
Weightlessness | 1 | 2020 | 102 | 0.650 |
Why?
|
Blood Platelet Disorders | 1 | 2019 | 60 | 0.650 |
Why?
|
Perioperative Care | 3 | 2024 | 1036 | 0.650 |
Why?
|
Contraceptives, Oral, Hormonal | 1 | 2020 | 190 | 0.650 |
Why?
|
Chemoprevention | 1 | 2021 | 326 | 0.650 |
Why?
|
Pyridines | 5 | 2021 | 2875 | 0.640 |
Why?
|
Janus Kinase 2 | 2 | 2021 | 560 | 0.640 |
Why?
|
Sex Reassignment Procedures | 1 | 2019 | 70 | 0.630 |
Why?
|
Designer Drugs | 1 | 2018 | 21 | 0.630 |
Why?
|
Blood Loss, Surgical | 2 | 2019 | 638 | 0.620 |
Why?
|
Stroke | 9 | 2024 | 9758 | 0.600 |
Why?
|
Heart Failure | 13 | 2024 | 11670 | 0.600 |
Why?
|
Antibodies, Antiphospholipid | 2 | 2018 | 71 | 0.600 |
Why?
|
Blood Group Incompatibility | 1 | 2018 | 135 | 0.590 |
Why?
|
Hemoptysis | 1 | 2019 | 152 | 0.590 |
Why?
|
Purpura, Thrombotic Thrombocytopenic | 2 | 2018 | 131 | 0.590 |
Why?
|
Risk Adjustment | 1 | 2021 | 600 | 0.580 |
Why?
|
Antiphospholipid Syndrome | 2 | 2022 | 165 | 0.580 |
Why?
|
Middle Aged | 111 | 2024 | 220920 | 0.580 |
Why?
|
Benzamides | 4 | 2021 | 1370 | 0.570 |
Why?
|
Female | 139 | 2024 | 392686 | 0.570 |
Why?
|
Space Flight | 1 | 2020 | 215 | 0.570 |
Why?
|
Risk Factors | 49 | 2024 | 74213 | 0.570 |
Why?
|
Vascular System Injuries | 1 | 2020 | 246 | 0.560 |
Why?
|
Male | 131 | 2024 | 360842 | 0.560 |
Why?
|
ABO Blood-Group System | 2 | 2018 | 380 | 0.550 |
Why?
|
Gastrointestinal Hemorrhage | 3 | 2024 | 1116 | 0.540 |
Why?
|
Plasma | 2 | 2019 | 586 | 0.540 |
Why?
|
Tranexamic Acid | 1 | 2019 | 176 | 0.530 |
Why?
|
beta-Alanine | 2 | 2014 | 82 | 0.530 |
Why?
|
Cannabinoids | 1 | 2018 | 172 | 0.530 |
Why?
|
Formularies as Topic | 1 | 2016 | 94 | 0.530 |
Why?
|
Extracorporeal Circulation | 1 | 2016 | 181 | 0.530 |
Why?
|
Randomized Controlled Trials as Topic | 10 | 2024 | 10212 | 0.520 |
Why?
|
Phenylthiohydantoin | 1 | 2017 | 205 | 0.520 |
Why?
|
Testicular Neoplasms | 2 | 2020 | 799 | 0.510 |
Why?
|
Factor VII Deficiency | 1 | 2015 | 31 | 0.510 |
Why?
|
Transsexualism | 1 | 2019 | 208 | 0.510 |
Why?
|
Gonadal Steroid Hormones | 1 | 2019 | 702 | 0.500 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 1 | 2020 | 491 | 0.500 |
Why?
|
Drug Resistance | 1 | 2021 | 1596 | 0.500 |
Why?
|
Aged | 76 | 2024 | 169310 | 0.480 |
Why?
|
Asparaginase | 4 | 2024 | 240 | 0.470 |
Why?
|
Factor XI | 3 | 2024 | 34 | 0.470 |
Why?
|
Adult | 95 | 2024 | 221203 | 0.460 |
Why?
|
von Willebrand Factor | 4 | 2024 | 673 | 0.450 |
Why?
|
Intracranial Hemorrhages | 2 | 2018 | 822 | 0.450 |
Why?
|
Retrospective Studies | 43 | 2024 | 80646 | 0.440 |
Why?
|
Vincristine | 21 | 2015 | 1036 | 0.440 |
Why?
|
Risk Assessment | 16 | 2024 | 23996 | 0.440 |
Why?
|
Benzimidazoles | 3 | 2014 | 858 | 0.440 |
Why?
|
Abortion, Habitual | 1 | 2014 | 61 | 0.440 |
Why?
|
Fibrinogen | 3 | 2022 | 888 | 0.430 |
Why?
|
Thiazoles | 2 | 2023 | 1517 | 0.430 |
Why?
|
Antibodies, Monoclonal | 7 | 2018 | 9177 | 0.430 |
Why?
|
Fibrinolysis | 3 | 2024 | 332 | 0.430 |
Why?
|
Emergencies | 1 | 2019 | 1217 | 0.420 |
Why?
|
Epidemics | 1 | 2018 | 512 | 0.410 |
Why?
|
Physician's Role | 1 | 2019 | 917 | 0.410 |
Why?
|
Prostate | 1 | 2021 | 1773 | 0.410 |
Why?
|
British Columbia | 11 | 2017 | 241 | 0.410 |
Why?
|
Vascular Diseases | 1 | 2020 | 1161 | 0.400 |
Why?
|
Drug Costs | 2 | 2019 | 1183 | 0.400 |
Why?
|
Practice Guidelines as Topic | 11 | 2022 | 7391 | 0.380 |
Why?
|
Cardiac Surgical Procedures | 2 | 2024 | 3627 | 0.370 |
Why?
|
Antifibrinolytic Agents | 3 | 2020 | 292 | 0.370 |
Why?
|
Prednisone | 20 | 2015 | 1563 | 0.370 |
Why?
|
Hematopoietic Stem Cell Transplantation | 6 | 2018 | 5672 | 0.370 |
Why?
|
Intensive Care Units | 3 | 2022 | 3744 | 0.370 |
Why?
|
Outpatients | 4 | 2022 | 1597 | 0.370 |
Why?
|
Gingival Hemorrhage | 2 | 2009 | 49 | 0.370 |
Why?
|
Cardiomyopathy, Dilated | 1 | 2017 | 829 | 0.360 |
Why?
|
Immunologic Factors | 3 | 2018 | 1589 | 0.360 |
Why?
|
Doxorubicin | 22 | 2017 | 2224 | 0.360 |
Why?
|
Hematologic Diseases | 1 | 2014 | 496 | 0.350 |
Why?
|
Lymphoma, Non-Hodgkin | 11 | 2008 | 1374 | 0.340 |
Why?
|
Treatment Outcome | 38 | 2024 | 64684 | 0.340 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2024 | 3245 | 0.340 |
Why?
|
Cyclophosphamide | 22 | 2015 | 2220 | 0.330 |
Why?
|
Hemosiderosis | 1 | 2010 | 66 | 0.330 |
Why?
|
Cost-Benefit Analysis | 3 | 2019 | 5492 | 0.330 |
Why?
|
Cystic Fibrosis | 1 | 2019 | 1285 | 0.330 |
Why?
|
Drug Approval | 1 | 2016 | 814 | 0.330 |
Why?
|
Disease Management | 6 | 2021 | 2508 | 0.330 |
Why?
|
Patient Education as Topic | 1 | 2019 | 2319 | 0.330 |
Why?
|
Platelet Count | 6 | 2023 | 781 | 0.320 |
Why?
|
Ambulatory Care | 3 | 2018 | 2775 | 0.310 |
Why?
|
Neoplasms, Second Primary | 6 | 2022 | 1052 | 0.310 |
Why?
|
Decision Support Systems, Clinical | 1 | 2018 | 1175 | 0.310 |
Why?
|
Myelodysplastic Syndromes | 1 | 2018 | 1394 | 0.310 |
Why?
|
Heart Transplantation | 3 | 2017 | 3233 | 0.310 |
Why?
|
Prognosis | 30 | 2021 | 29629 | 0.300 |
Why?
|
Drug Therapy, Combination | 1 | 2018 | 6312 | 0.300 |
Why?
|
Prostate-Specific Antigen | 1 | 2017 | 2469 | 0.300 |
Why?
|
Labor, Obstetric | 1 | 2011 | 323 | 0.290 |
Why?
|
Bleomycin | 13 | 2017 | 494 | 0.290 |
Why?
|
Aged, 80 and over | 31 | 2021 | 58986 | 0.290 |
Why?
|
Pregnancy | 17 | 2022 | 29876 | 0.290 |
Why?
|
Registries | 6 | 2021 | 8224 | 0.280 |
Why?
|
Mediastinal Neoplasms | 2 | 2009 | 401 | 0.270 |
Why?
|
Delivery, Obstetric | 2 | 2011 | 940 | 0.270 |
Why?
|
Cardiopulmonary Bypass | 3 | 2024 | 1092 | 0.270 |
Why?
|
Lymphoma, B-Cell | 6 | 2005 | 940 | 0.270 |
Why?
|
Clinical Trials as Topic | 6 | 2022 | 8002 | 0.250 |
Why?
|
Combined Modality Therapy | 22 | 2016 | 8528 | 0.250 |
Why?
|
Enoxaparin | 2 | 2020 | 391 | 0.250 |
Why?
|
Critical Care | 5 | 2024 | 2697 | 0.240 |
Why?
|
Lung Neoplasms | 3 | 2020 | 13382 | 0.240 |
Why?
|
Leukemia, Hairy Cell | 4 | 1998 | 82 | 0.240 |
Why?
|
Markov Chains | 2 | 2019 | 966 | 0.240 |
Why?
|
Drug Administration Schedule | 9 | 2020 | 4853 | 0.230 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2015 | 2118 | 0.230 |
Why?
|
Anesthesia, Obstetrical | 2 | 2021 | 233 | 0.230 |
Why?
|
Whole Blood Coagulation Time | 1 | 2024 | 30 | 0.230 |
Why?
|
Secondary Prevention | 2 | 2021 | 1475 | 0.230 |
Why?
|
Tissue Plasminogen Activator | 2 | 2021 | 1164 | 0.230 |
Why?
|
Cardiomyopathies | 2 | 2015 | 1964 | 0.220 |
Why?
|
Bone Marrow Transplantation | 12 | 2000 | 2693 | 0.220 |
Why?
|
Prospective Studies | 18 | 2024 | 54426 | 0.220 |
Why?
|
Hospitalization | 7 | 2023 | 10721 | 0.220 |
Why?
|
Pharmaceutical Preparations | 2 | 2022 | 1089 | 0.220 |
Why?
|
Polydeoxyribonucleotides | 1 | 2024 | 136 | 0.210 |
Why?
|
Postoperative Hemorrhage | 2 | 2018 | 415 | 0.210 |
Why?
|
Syndrome | 3 | 2022 | 3267 | 0.210 |
Why?
|
Lymphoma, T-Cell, Peripheral | 1 | 2004 | 125 | 0.210 |
Why?
|
Multiple Myeloma | 5 | 2024 | 5146 | 0.210 |
Why?
|
Lymphoma | 7 | 1997 | 1901 | 0.210 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2015 | 5305 | 0.210 |
Why?
|
Disease-Free Survival | 11 | 2017 | 6815 | 0.200 |
Why?
|
Lymphoma, Mantle-Cell | 3 | 2017 | 237 | 0.200 |
Why?
|
Heart Ventricles | 4 | 2019 | 3807 | 0.200 |
Why?
|
Antithrombin III Deficiency | 1 | 2021 | 28 | 0.190 |
Why?
|
Dose-Response Relationship, Drug | 7 | 2021 | 10766 | 0.190 |
Why?
|
Sepsis | 3 | 2022 | 2585 | 0.190 |
Why?
|
Early Termination of Clinical Trials | 1 | 2021 | 69 | 0.190 |
Why?
|
Incidence | 12 | 2024 | 21355 | 0.190 |
Why?
|
Quality-Adjusted Life Years | 2 | 2019 | 1722 | 0.190 |
Why?
|
Neoplasm Recurrence, Local | 7 | 2021 | 9280 | 0.190 |
Why?
|
L-Lactate Dehydrogenase | 2 | 2020 | 411 | 0.180 |
Why?
|
Endothelium, Vascular | 3 | 2024 | 4431 | 0.180 |
Why?
|
Transplantation, Autologous | 8 | 2014 | 2115 | 0.180 |
Why?
|
Disease Progression | 7 | 2024 | 13510 | 0.180 |
Why?
|
Costs and Cost Analysis | 2 | 2016 | 1668 | 0.180 |
Why?
|
Prothrombin Time | 1 | 2020 | 117 | 0.170 |
Why?
|
Neoplasm Staging | 13 | 2019 | 11121 | 0.170 |
Why?
|
Foramen Ovale, Patent | 1 | 2023 | 208 | 0.170 |
Why?
|
Transplantation, Homologous | 9 | 2018 | 4807 | 0.170 |
Why?
|
Academic Medical Centers | 4 | 2018 | 2759 | 0.170 |
Why?
|
Pregnancy Complications | 1 | 2014 | 2947 | 0.170 |
Why?
|
Lung Diseases | 1 | 2010 | 1909 | 0.170 |
Why?
|
Patients | 2 | 2023 | 907 | 0.170 |
Why?
|
Antineoplastic Agents | 9 | 2021 | 13642 | 0.160 |
Why?
|
Thiophenes | 1 | 2023 | 569 | 0.160 |
Why?
|
Thrombocythemia, Essential | 1 | 2020 | 113 | 0.160 |
Why?
|
Communication | 2 | 2024 | 3873 | 0.160 |
Why?
|
Etoposide | 10 | 2005 | 634 | 0.160 |
Why?
|
Geriatrics | 1 | 2023 | 388 | 0.160 |
Why?
|
Lymphopenia | 1 | 2021 | 281 | 0.160 |
Why?
|
Off-Label Use | 1 | 2020 | 185 | 0.160 |
Why?
|
Illinois | 1 | 2018 | 120 | 0.150 |
Why?
|
Plasma Exchange | 2 | 2018 | 159 | 0.150 |
Why?
|
Live Birth | 2 | 2020 | 511 | 0.150 |
Why?
|
Inflammasomes | 1 | 2023 | 526 | 0.150 |
Why?
|
Hermanski-Pudlak Syndrome | 1 | 2018 | 20 | 0.150 |
Why?
|
Medication Therapy Management | 1 | 2019 | 130 | 0.150 |
Why?
|
Drug and Narcotic Control | 1 | 2019 | 144 | 0.150 |
Why?
|
Abortion, Spontaneous | 2 | 2020 | 533 | 0.150 |
Why?
|
Comorbidity | 6 | 2024 | 10508 | 0.150 |
Why?
|
Body Weight | 2 | 2019 | 4618 | 0.150 |
Why?
|
Cerebral Hemorrhage | 2 | 2019 | 2656 | 0.140 |
Why?
|
Lymphoma, B-Cell, Marginal Zone | 1 | 1999 | 178 | 0.140 |
Why?
|
Ferritins | 1 | 2020 | 598 | 0.140 |
Why?
|
Genes, bcl-2 | 1 | 1997 | 119 | 0.140 |
Why?
|
Aneurysm, False | 1 | 2019 | 255 | 0.140 |
Why?
|
Shock | 1 | 2019 | 314 | 0.140 |
Why?
|
Blood Platelets | 3 | 2023 | 2479 | 0.140 |
Why?
|
Hemoglobinuria, Paroxysmal | 1 | 2017 | 94 | 0.140 |
Why?
|
Protein-Tyrosine Kinases | 2 | 2023 | 2425 | 0.130 |
Why?
|
Time Factors | 14 | 2024 | 39970 | 0.130 |
Why?
|
Leucovorin | 5 | 2005 | 643 | 0.130 |
Why?
|
Clinical Protocols | 4 | 2018 | 1440 | 0.130 |
Why?
|
Vasoconstrictor Agents | 1 | 2019 | 654 | 0.130 |
Why?
|
Intraoperative Care | 1 | 2019 | 767 | 0.130 |
Why?
|
Cesarean Section | 3 | 2021 | 1398 | 0.130 |
Why?
|
Limit of Detection | 1 | 2016 | 273 | 0.130 |
Why?
|
Bone Marrow Diseases | 1 | 2017 | 233 | 0.130 |
Why?
|
Gastrointestinal Diseases | 1 | 2024 | 1200 | 0.120 |
Why?
|
Anemia, Aplastic | 1 | 2017 | 230 | 0.120 |
Why?
|
Accidents, Traffic | 1 | 2001 | 816 | 0.120 |
Why?
|
Critical Pathways | 1 | 2019 | 474 | 0.120 |
Why?
|
Vasodilation | 1 | 2019 | 962 | 0.120 |
Why?
|
Algorithms | 4 | 2019 | 14032 | 0.120 |
Why?
|
Patient Selection | 3 | 2021 | 4244 | 0.120 |
Why?
|
Vinblastine | 6 | 2017 | 488 | 0.120 |
Why?
|
Chromatography, Liquid | 1 | 2018 | 983 | 0.120 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2019 | 4016 | 0.120 |
Why?
|
Postoperative Complications | 4 | 2019 | 15633 | 0.120 |
Why?
|
Factor VIII | 2 | 2023 | 348 | 0.120 |
Why?
|
Models, Theoretical | 2 | 2019 | 3575 | 0.120 |
Why?
|
Wounds, Nonpenetrating | 1 | 2001 | 807 | 0.120 |
Why?
|
Bone Neoplasms | 1 | 2006 | 2529 | 0.120 |
Why?
|
Adolescent | 29 | 2024 | 88324 | 0.110 |
Why?
|
Ductus Arteriosus, Patent | 1 | 2016 | 217 | 0.110 |
Why?
|
Extremities | 1 | 2019 | 867 | 0.110 |
Why?
|
Drug Interactions | 1 | 2018 | 1416 | 0.110 |
Why?
|
Immunoglobulin G | 3 | 2018 | 4544 | 0.110 |
Why?
|
Drug Utilization Review | 1 | 2014 | 248 | 0.110 |
Why?
|
Diagnostic Errors | 1 | 2001 | 1265 | 0.110 |
Why?
|
Receptor Protein-Tyrosine Kinases | 2 | 2020 | 1626 | 0.110 |
Why?
|
Propensity Score | 1 | 2021 | 1913 | 0.110 |
Why?
|
Watchful Waiting | 1 | 2017 | 491 | 0.110 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 4 | 1999 | 1406 | 0.110 |
Why?
|
Aorta, Thoracic | 1 | 2019 | 1096 | 0.110 |
Why?
|
Stem Cell Transplantation | 2 | 2014 | 1600 | 0.110 |
Why?
|
Proto-Oncogene Proteins | 2 | 2023 | 4513 | 0.110 |
Why?
|
Legislation, Drug | 1 | 2015 | 214 | 0.100 |
Why?
|
Pilot Projects | 2 | 2024 | 8633 | 0.100 |
Why?
|
Leukocytes | 1 | 2021 | 2026 | 0.100 |
Why?
|
Health Resources | 1 | 2019 | 935 | 0.100 |
Why?
|
Thrombolytic Therapy | 2 | 2021 | 2064 | 0.100 |
Why?
|
Shock, Septic | 1 | 2019 | 768 | 0.100 |
Why?
|
Nuclear Physics | 1 | 2012 | 75 | 0.100 |
Why?
|
Oncology Service, Hospital | 1 | 2012 | 57 | 0.100 |
Why?
|
Creatinine | 2 | 2016 | 1899 | 0.100 |
Why?
|
Prosthesis Implantation | 1 | 2017 | 592 | 0.100 |
Why?
|
Young Adult | 9 | 2024 | 59255 | 0.100 |
Why?
|
Nitriles | 1 | 2017 | 971 | 0.100 |
Why?
|
Pharmacists | 1 | 2014 | 260 | 0.100 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2016 | 3810 | 0.100 |
Why?
|
Postoperative Care | 1 | 2019 | 1468 | 0.100 |
Why?
|
United States | 9 | 2022 | 72335 | 0.100 |
Why?
|
Forecasting | 1 | 2021 | 2928 | 0.100 |
Why?
|
Tandem Mass Spectrometry | 1 | 2018 | 1188 | 0.100 |
Why?
|
Vaccination | 1 | 2024 | 3384 | 0.100 |
Why?
|
Lung Transplantation | 2 | 2018 | 1310 | 0.100 |
Why?
|
Enterocolitis, Necrotizing | 1 | 2016 | 326 | 0.100 |
Why?
|
Organ Transplantation | 1 | 2022 | 1157 | 0.100 |
Why?
|
Hematologic Tests | 2 | 2009 | 239 | 0.100 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2019 | 954 | 0.100 |
Why?
|
Neutrophils | 3 | 2021 | 3767 | 0.100 |
Why?
|
Survival Analysis | 10 | 2020 | 10090 | 0.100 |
Why?
|
Nurses | 2 | 2018 | 2478 | 0.100 |
Why?
|
Survival Rate | 14 | 2009 | 12725 | 0.090 |
Why?
|
Methotrexate | 5 | 2005 | 1719 | 0.090 |
Why?
|
Leukocyte Transfusion | 3 | 2000 | 56 | 0.090 |
Why?
|
Double-Blind Method | 2 | 2023 | 12341 | 0.090 |
Why?
|
Aftercare | 3 | 2022 | 914 | 0.090 |
Why?
|
Ischemia | 1 | 2019 | 1883 | 0.090 |
Why?
|
Acute Disease | 4 | 2024 | 7237 | 0.090 |
Why?
|
Preoperative Care | 1 | 2019 | 2242 | 0.090 |
Why?
|
Thrombopoietin | 2 | 2023 | 226 | 0.090 |
Why?
|
Anesthesia, Epidural | 2 | 2009 | 233 | 0.090 |
Why?
|
Translocation, Genetic | 3 | 2000 | 1393 | 0.080 |
Why?
|
Cohort Studies | 9 | 2023 | 41493 | 0.080 |
Why?
|
Dental Scaling | 1 | 2009 | 107 | 0.080 |
Why?
|
Drug Hypersensitivity | 1 | 2018 | 917 | 0.080 |
Why?
|
Anesthesia, Spinal | 2 | 2009 | 280 | 0.080 |
Why?
|
Critical Illness | 4 | 2023 | 2723 | 0.080 |
Why?
|
Pregnancy Complications, Infectious | 1 | 2021 | 2151 | 0.080 |
Why?
|
Iohexol | 1 | 2010 | 204 | 0.080 |
Why?
|
Graft vs Host Disease | 6 | 2017 | 3029 | 0.080 |
Why?
|
Procarbazine | 4 | 1997 | 172 | 0.080 |
Why?
|
Mechlorethamine | 4 | 1997 | 129 | 0.080 |
Why?
|
Lung | 4 | 2022 | 10002 | 0.080 |
Why?
|
Disease Outbreaks | 1 | 2018 | 1749 | 0.080 |
Why?
|
Cladribine | 2 | 1998 | 34 | 0.080 |
Why?
|
Emergency Service, Hospital | 3 | 2023 | 7879 | 0.080 |
Why?
|
Anthracyclines | 1 | 2010 | 284 | 0.080 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 5 | 2015 | 694 | 0.080 |
Why?
|
C-Reactive Protein | 1 | 2020 | 3826 | 0.080 |
Why?
|
Carcinoma, Pancreatic Ductal | 1 | 2019 | 1728 | 0.080 |
Why?
|
Severity of Illness Index | 3 | 2021 | 15843 | 0.080 |
Why?
|
Dacarbazine | 4 | 2017 | 559 | 0.080 |
Why?
|
Physicians | 2 | 2019 | 4591 | 0.080 |
Why?
|
Chromosomes, Human, Pair 8 | 2 | 2000 | 453 | 0.080 |
Why?
|
Erythropoietin | 1 | 2012 | 719 | 0.080 |
Why?
|
Inflammation | 3 | 2023 | 10773 | 0.080 |
Why?
|
Aortic Aneurysm, Thoracic | 1 | 2014 | 696 | 0.080 |
Why?
|
Health Behavior | 1 | 2019 | 2644 | 0.070 |
Why?
|
Guideline Adherence | 1 | 2018 | 2220 | 0.070 |
Why?
|
Splenectomy | 4 | 1998 | 391 | 0.070 |
Why?
|
Hospitals | 1 | 2021 | 3882 | 0.070 |
Why?
|
Age Factors | 4 | 2019 | 18398 | 0.070 |
Why?
|
Diagnosis, Differential | 5 | 2010 | 12975 | 0.070 |
Why?
|
Referral and Consultation | 1 | 2020 | 3600 | 0.070 |
Why?
|
Analgesia, Obstetrical | 1 | 2009 | 169 | 0.070 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2019 | 3639 | 0.070 |
Why?
|
Ultrasonography | 1 | 2020 | 5972 | 0.070 |
Why?
|
Kaplan-Meier Estimate | 4 | 2017 | 6484 | 0.070 |
Why?
|
Follow-Up Studies | 13 | 2020 | 39107 | 0.070 |
Why?
|
Renal Dialysis | 1 | 2016 | 1796 | 0.070 |
Why?
|
Wounds and Injuries | 1 | 2019 | 2491 | 0.070 |
Why?
|
Pregnancy Outcome | 1 | 2017 | 2922 | 0.070 |
Why?
|
Lymphoma, Follicular | 1 | 2010 | 457 | 0.070 |
Why?
|
Physician-Patient Relations | 1 | 2019 | 3249 | 0.070 |
Why?
|
Predictive Value of Tests | 7 | 2022 | 15266 | 0.070 |
Why?
|
Vascular Surgical Procedures | 1 | 2014 | 1489 | 0.060 |
Why?
|
Attitude of Health Personnel | 1 | 2019 | 3889 | 0.060 |
Why?
|
Infant, Premature | 1 | 2015 | 2107 | 0.060 |
Why?
|
Molecular Targeted Therapy | 1 | 2016 | 2811 | 0.060 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2020 | 3615 | 0.060 |
Why?
|
Databases as Topic | 1 | 2006 | 473 | 0.060 |
Why?
|
Patient Readmission | 1 | 2019 | 3271 | 0.060 |
Why?
|
Stomatitis | 1 | 1987 | 271 | 0.060 |
Why?
|
Age Distribution | 4 | 2011 | 2880 | 0.060 |
Why?
|
Models, Biological | 1 | 2020 | 9469 | 0.060 |
Why?
|
Actuarial Analysis | 3 | 1997 | 372 | 0.060 |
Why?
|
Child | 11 | 2021 | 80156 | 0.060 |
Why?
|
Interferon Type I | 2 | 1985 | 562 | 0.060 |
Why?
|
Patient Discharge | 3 | 2022 | 3443 | 0.060 |
Why?
|
Recombinant Fusion Proteins | 2 | 2023 | 3733 | 0.060 |
Why?
|
Living Donors | 1 | 2008 | 641 | 0.060 |
Why?
|
Clinical Competence | 1 | 2019 | 4793 | 0.060 |
Why?
|
Blood Transfusion | 1 | 1990 | 1301 | 0.050 |
Why?
|
Acute Kidney Injury | 1 | 2016 | 1924 | 0.050 |
Why?
|
Radiography, Thoracic | 1 | 2010 | 1302 | 0.050 |
Why?
|
Platelet Aggregation | 2 | 2020 | 771 | 0.050 |
Why?
|
Stromal Cells | 1 | 2008 | 1330 | 0.050 |
Why?
|
Nasopharyngeal Neoplasms | 1 | 1985 | 290 | 0.050 |
Why?
|
Myocardial Infarction | 2 | 2023 | 11461 | 0.050 |
Why?
|
Disease Susceptibility | 2 | 2021 | 1787 | 0.050 |
Why?
|
Biopsy | 4 | 2010 | 6766 | 0.050 |
Why?
|
Peripheral Blood Stem Cell Transplantation | 1 | 2004 | 263 | 0.050 |
Why?
|
Tumor Virus Infections | 1 | 1985 | 438 | 0.050 |
Why?
|
Transients and Migrants | 1 | 2005 | 165 | 0.050 |
Why?
|
Graft vs Tumor Effect | 2 | 1999 | 68 | 0.050 |
Why?
|
Lymphoma, Large-Cell, Immunoblastic | 2 | 2002 | 25 | 0.050 |
Why?
|
Radiotherapy | 2 | 2006 | 1499 | 0.050 |
Why?
|
Body Mass Index | 2 | 2019 | 12954 | 0.050 |
Why?
|
Reproducibility of Results | 2 | 2019 | 20099 | 0.050 |
Why?
|
Pancreatic Neoplasms | 1 | 2019 | 5369 | 0.050 |
Why?
|
Case-Control Studies | 3 | 2018 | 22176 | 0.050 |
Why?
|
Celiac Disease | 1 | 2010 | 821 | 0.050 |
Why?
|
Prosthesis Design | 2 | 2019 | 2115 | 0.050 |
Why?
|
Genes, myc | 2 | 2000 | 390 | 0.050 |
Why?
|
Mutation | 2 | 2021 | 30054 | 0.050 |
Why?
|
Bone Marrow | 6 | 1997 | 2911 | 0.050 |
Why?
|
Central Nervous System Neoplasms | 1 | 2009 | 916 | 0.050 |
Why?
|
Drug Evaluation | 2 | 2014 | 641 | 0.050 |
Why?
|
Medical Records | 1 | 2006 | 1408 | 0.050 |
Why?
|
Multivariate Analysis | 7 | 2008 | 12059 | 0.050 |
Why?
|
Medicare | 1 | 2019 | 6770 | 0.050 |
Why?
|
Inappropriate Prescribing | 1 | 2023 | 211 | 0.050 |
Why?
|
Cardiovascular Diseases | 2 | 2024 | 15501 | 0.050 |
Why?
|
Arginine | 1 | 2024 | 934 | 0.040 |
Why?
|
Life Tables | 2 | 1998 | 364 | 0.040 |
Why?
|
Interferon-alpha | 3 | 1999 | 921 | 0.040 |
Why?
|
Leukocyte Count | 3 | 2021 | 1596 | 0.040 |
Why?
|
Transplantation Conditioning | 3 | 2008 | 1590 | 0.040 |
Why?
|
Ohio | 1 | 2001 | 322 | 0.040 |
Why?
|
Sensitivity and Specificity | 3 | 2022 | 14666 | 0.040 |
Why?
|
Infant, Newborn | 6 | 2017 | 26198 | 0.040 |
Why?
|
Embryonic and Fetal Development | 1 | 2001 | 420 | 0.040 |
Why?
|
Traumatology | 1 | 2001 | 100 | 0.040 |
Why?
|
Blood Cell Count | 1 | 2021 | 397 | 0.040 |
Why?
|
PubMed | 1 | 2020 | 129 | 0.040 |
Why?
|
Post-Exposure Prophylaxis | 1 | 2021 | 110 | 0.040 |
Why?
|
Birth Weight | 2 | 2015 | 2103 | 0.040 |
Why?
|
Lymphoma, T-Cell | 2 | 1999 | 304 | 0.040 |
Why?
|
Maternal Mortality | 1 | 2022 | 302 | 0.040 |
Why?
|
Multicenter Studies as Topic | 2 | 2018 | 1702 | 0.040 |
Why?
|
Herpesvirus 4, Human | 1 | 1985 | 1078 | 0.040 |
Why?
|
Maternal Age | 1 | 2022 | 809 | 0.040 |
Why?
|
Quality Improvement | 1 | 2014 | 3801 | 0.040 |
Why?
|
Insulin-Like Growth Factor II | 1 | 2001 | 269 | 0.040 |
Why?
|
Utah | 1 | 2019 | 131 | 0.040 |
Why?
|
Diagnostic Techniques, Cardiovascular | 1 | 2020 | 148 | 0.040 |
Why?
|
Centrifugation | 1 | 2019 | 122 | 0.040 |
Why?
|
Postal Service | 1 | 1979 | 96 | 0.040 |
Why?
|
Pentostatin | 1 | 1998 | 26 | 0.040 |
Why?
|
Insulin-Like Growth Factor Binding Protein 3 | 1 | 2001 | 416 | 0.040 |
Why?
|
Intention to Treat Analysis | 1 | 2020 | 413 | 0.040 |
Why?
|
Infusions, Intravenous | 2 | 2017 | 2218 | 0.040 |
Why?
|
Patient Advocacy | 1 | 2021 | 360 | 0.040 |
Why?
|
Autopsy | 1 | 2022 | 1009 | 0.040 |
Why?
|
Chromosomes, Human, Pair 18 | 1 | 1999 | 247 | 0.040 |
Why?
|
Catheters | 1 | 2021 | 427 | 0.040 |
Why?
|
Quality of Life | 4 | 2023 | 13367 | 0.040 |
Why?
|
Injections, Subcutaneous | 1 | 2020 | 681 | 0.040 |
Why?
|
Cause of Death | 2 | 2022 | 3683 | 0.040 |
Why?
|
France | 1 | 2019 | 497 | 0.040 |
Why?
|
Sus scrofa | 1 | 2020 | 428 | 0.040 |
Why?
|
Urinalysis | 1 | 2000 | 368 | 0.040 |
Why?
|
Thrombin | 1 | 2021 | 591 | 0.040 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2006 | 3514 | 0.040 |
Why?
|
Megakaryocytes | 1 | 2022 | 567 | 0.040 |
Why?
|
Chromosomes, Human, Pair 3 | 1 | 1999 | 322 | 0.040 |
Why?
|
Burkitt Lymphoma | 1 | 2000 | 335 | 0.040 |
Why?
|
Infusion Pumps | 1 | 2019 | 163 | 0.040 |
Why?
|
Lactation Disorders | 1 | 2017 | 14 | 0.040 |
Why?
|
Comparative Effectiveness Research | 1 | 2023 | 709 | 0.040 |
Why?
|
Endothelial Cells | 2 | 2021 | 3548 | 0.040 |
Why?
|
Diagnostic Imaging | 3 | 2000 | 3530 | 0.040 |
Why?
|
Interleukin-1beta | 1 | 2023 | 999 | 0.040 |
Why?
|
Cholecystectomy, Laparoscopic | 1 | 2019 | 232 | 0.040 |
Why?
|
Pulmonary Edema | 1 | 2020 | 409 | 0.040 |
Why?
|
Gender Identity | 1 | 2023 | 766 | 0.040 |
Why?
|
Receptors, Fc | 1 | 2021 | 535 | 0.040 |
Why?
|
Injury Severity Score | 1 | 2001 | 1045 | 0.040 |
Why?
|
Sex Distribution | 2 | 1999 | 2281 | 0.040 |
Why?
|
Emergency Treatment | 1 | 2001 | 496 | 0.030 |
Why?
|
Medication Errors | 1 | 2023 | 783 | 0.030 |
Why?
|
Treatment Failure | 2 | 2015 | 2644 | 0.030 |
Why?
|
Nurse's Role | 1 | 2018 | 188 | 0.030 |
Why?
|
Lymphoproliferative Disorders | 1 | 2000 | 531 | 0.030 |
Why?
|
Contrast Media | 1 | 2010 | 5311 | 0.030 |
Why?
|
Fatal Outcome | 2 | 2017 | 1835 | 0.030 |
Why?
|
Vena Cava Filters | 1 | 2019 | 261 | 0.030 |
Why?
|
False Negative Reactions | 1 | 2017 | 573 | 0.030 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 1999 | 686 | 0.030 |
Why?
|
Single-Blind Method | 1 | 2020 | 1574 | 0.030 |
Why?
|
Microvessels | 1 | 2020 | 577 | 0.030 |
Why?
|
Gene Expression | 1 | 2008 | 7581 | 0.030 |
Why?
|
Gene Rearrangement | 2 | 1999 | 1125 | 0.030 |
Why?
|
Early Diagnosis | 1 | 2021 | 1186 | 0.030 |
Why?
|
Systemic Inflammatory Response Syndrome | 1 | 2021 | 621 | 0.030 |
Why?
|
Ticlopidine | 1 | 2000 | 730 | 0.030 |
Why?
|
Fetal Death | 1 | 2017 | 435 | 0.030 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2001 | 1784 | 0.030 |
Why?
|
Neoadjuvant Therapy | 1 | 2006 | 2827 | 0.030 |
Why?
|
Stockings, Compression | 1 | 2015 | 36 | 0.030 |
Why?
|
Organization and Administration | 1 | 2014 | 54 | 0.030 |
Why?
|
Necrosis | 1 | 2019 | 1611 | 0.030 |
Why?
|
Chorionic Villi | 1 | 2015 | 53 | 0.030 |
Why?
|
Phenotype | 2 | 2023 | 16592 | 0.030 |
Why?
|
Clinical Laboratory Techniques | 1 | 2020 | 746 | 0.030 |
Why?
|
Drug Substitution | 1 | 2017 | 290 | 0.030 |
Why?
|
Delivery of Health Care | 2 | 2023 | 5336 | 0.030 |
Why?
|
Interferons | 1 | 1998 | 706 | 0.030 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 1998 | 646 | 0.030 |
Why?
|
Immunoglobulin M | 2 | 2018 | 1526 | 0.030 |
Why?
|
Carmustine | 4 | 1999 | 138 | 0.030 |
Why?
|
Urinary Tract Infections | 1 | 2000 | 802 | 0.030 |
Why?
|
Fetal Blood | 1 | 2001 | 1347 | 0.030 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2000 | 612 | 0.030 |
Why?
|
Pulmonary Fibrosis | 1 | 2018 | 505 | 0.030 |
Why?
|
Protein Multimerization | 1 | 2019 | 983 | 0.030 |
Why?
|
Pregnancy, Multiple | 1 | 2015 | 215 | 0.030 |
Why?
|
Hemostatic Techniques | 1 | 2014 | 112 | 0.030 |
Why?
|
Hematoma | 1 | 2018 | 767 | 0.030 |
Why?
|
Piperazines | 1 | 2024 | 2523 | 0.030 |
Why?
|
Pharmacy Service, Hospital | 1 | 2014 | 134 | 0.030 |
Why?
|
China | 1 | 2020 | 2374 | 0.030 |
Why?
|
Drug Industry | 1 | 2020 | 788 | 0.030 |
Why?
|
Nuclear Energy | 1 | 2012 | 15 | 0.030 |
Why?
|
Sex Factors | 2 | 2019 | 10553 | 0.030 |
Why?
|
Anemia, Refractory | 1 | 1992 | 17 | 0.030 |
Why?
|
Bone Marrow Purging | 1 | 1993 | 108 | 0.030 |
Why?
|
Infant, Very Low Birth Weight | 1 | 2016 | 407 | 0.030 |
Why?
|
Insulin-Like Growth Factor I | 1 | 2001 | 1935 | 0.030 |
Why?
|
Leptin | 1 | 2001 | 1597 | 0.030 |
Why?
|
Gene Expression Profiling | 1 | 2008 | 9420 | 0.030 |
Why?
|
Consensus | 1 | 2022 | 3123 | 0.030 |
Why?
|
Endoscopy, Gastrointestinal | 1 | 2019 | 874 | 0.030 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2023 | 3492 | 0.030 |
Why?
|
Telomerase | 1 | 2017 | 745 | 0.030 |
Why?
|
Antithrombin Proteins | 1 | 2011 | 10 | 0.020 |
Why?
|
Fluid Therapy | 1 | 2016 | 579 | 0.020 |
Why?
|
Host-Pathogen Interactions | 1 | 2020 | 1459 | 0.020 |
Why?
|
Anemia, Sideroblastic | 1 | 1992 | 109 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 2 | 2017 | 20571 | 0.020 |
Why?
|
Hyperlipoproteinemias | 1 | 1991 | 20 | 0.020 |
Why?
|
Canada | 1 | 1997 | 2122 | 0.020 |
Why?
|
Hospitals, Pediatric | 1 | 2001 | 1860 | 0.020 |
Why?
|
Europe | 1 | 2018 | 3422 | 0.020 |
Why?
|
Serotonin | 1 | 2016 | 1041 | 0.020 |
Why?
|
Polymerase Chain Reaction | 2 | 1999 | 6075 | 0.020 |
Why?
|
Inflammation Mediators | 1 | 2020 | 1886 | 0.020 |
Why?
|
Infertility, Female | 1 | 2017 | 760 | 0.020 |
Why?
|
Gestational Age | 2 | 2016 | 3577 | 0.020 |
Why?
|
Karyotyping | 3 | 1999 | 1171 | 0.020 |
Why?
|
Economics, Pharmaceutical | 1 | 2011 | 87 | 0.020 |
Why?
|
Stress, Mechanical | 1 | 2016 | 1674 | 0.020 |
Why?
|
Salvage Therapy | 1 | 1997 | 1264 | 0.020 |
Why?
|
Withholding Treatment | 1 | 2015 | 617 | 0.020 |
Why?
|
Renal Insufficiency | 1 | 2016 | 809 | 0.020 |
Why?
|
Leukapheresis | 1 | 1990 | 134 | 0.020 |
Why?
|
Terminology as Topic | 1 | 1997 | 1530 | 0.020 |
Why?
|
Infant, Premature, Diseases | 1 | 2016 | 710 | 0.020 |
Why?
|
Hypergammaglobulinemia | 1 | 2009 | 71 | 0.020 |
Why?
|
Databases, Factual | 2 | 2021 | 7967 | 0.020 |
Why?
|
Lymphocyte Activation | 1 | 2000 | 5485 | 0.020 |
Why?
|
Arizona | 1 | 1989 | 107 | 0.020 |
Why?
|
Mortality | 1 | 2021 | 2901 | 0.020 |
Why?
|
Statistics as Topic | 1 | 2016 | 2358 | 0.020 |
Why?
|
Autoantibodies | 1 | 2018 | 2116 | 0.020 |
Why?
|
Hepatitis C | 1 | 1999 | 1584 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2021 | 3060 | 0.020 |
Why?
|
Immunophenotyping | 3 | 1999 | 1869 | 0.020 |
Why?
|
Age of Onset | 1 | 2016 | 3306 | 0.020 |
Why?
|
Inpatients | 1 | 2020 | 2548 | 0.020 |
Why?
|
Evidence-Based Medicine | 1 | 2001 | 3688 | 0.020 |
Why?
|
Stomach Neoplasms | 1 | 1999 | 1459 | 0.020 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2000 | 1640 | 0.020 |
Why?
|
Immunotherapy | 1 | 2024 | 4652 | 0.020 |
Why?
|
Lymphatic Metastasis | 2 | 1999 | 2915 | 0.020 |
Why?
|
Medication Adherence | 1 | 2020 | 2176 | 0.020 |
Why?
|
Genetic Predisposition to Disease | 1 | 2009 | 17904 | 0.020 |
Why?
|
Genes, MHC Class II | 1 | 2008 | 434 | 0.020 |
Why?
|
Vasoactive Intestinal Peptide | 1 | 1988 | 180 | 0.020 |
Why?
|
RNA | 1 | 2017 | 2726 | 0.020 |
Why?
|
Monte Carlo Method | 1 | 2012 | 1258 | 0.020 |
Why?
|
Protons | 1 | 2012 | 1116 | 0.020 |
Why?
|
Length of Stay | 1 | 2001 | 6426 | 0.020 |
Why?
|
Immunohistochemistry | 2 | 1997 | 11076 | 0.020 |
Why?
|
Kidney | 1 | 2022 | 7047 | 0.020 |
Why?
|
Remission Induction | 3 | 1999 | 2397 | 0.020 |
Why?
|
Triiodothyronine | 1 | 1988 | 493 | 0.020 |
Why?
|
Prevalence | 2 | 2020 | 15732 | 0.020 |
Why?
|
Risk | 1 | 1998 | 9610 | 0.020 |
Why?
|
United States Food and Drug Administration | 1 | 2014 | 1664 | 0.020 |
Why?
|
Logistic Models | 1 | 2001 | 13255 | 0.020 |
Why?
|
Orchiectomy | 1 | 1988 | 463 | 0.020 |
Why?
|
Epidemiologic Methods | 1 | 2011 | 1336 | 0.020 |
Why?
|
Germinal Center | 1 | 2008 | 380 | 0.020 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2016 | 2273 | 0.020 |
Why?
|
Pediatrics | 1 | 2001 | 3589 | 0.020 |
Why?
|
Proportional Hazards Models | 1 | 2020 | 12463 | 0.020 |
Why?
|
Data Collection | 1 | 2014 | 3322 | 0.020 |
Why?
|
Acute Coronary Syndrome | 1 | 2018 | 2190 | 0.020 |
Why?
|
Siblings | 1 | 2009 | 825 | 0.020 |
Why?
|
Phorbols | 1 | 1984 | 43 | 0.010 |
Why?
|
Thyroxine | 1 | 1988 | 666 | 0.010 |
Why?
|
Mass Screening | 1 | 2020 | 5428 | 0.010 |
Why?
|
Phorbol Esters | 1 | 1984 | 108 | 0.010 |
Why?
|
Pneumonia, Pneumocystis | 1 | 1985 | 242 | 0.010 |
Why?
|
Hospitals, General | 1 | 2008 | 798 | 0.010 |
Why?
|
Poisson Distribution | 1 | 2005 | 504 | 0.010 |
Why?
|
Matched-Pair Analysis | 1 | 2004 | 284 | 0.010 |
Why?
|
Data Interpretation, Statistical | 1 | 2012 | 2691 | 0.010 |
Why?
|
Nausea | 1 | 1985 | 679 | 0.010 |
Why?
|
Leukemia | 2 | 1999 | 1522 | 0.010 |
Why?
|
Palliative Care | 1 | 1997 | 3598 | 0.010 |
Why?
|
Vomiting | 1 | 1985 | 651 | 0.010 |
Why?
|
Anesthesia, General | 1 | 2009 | 1174 | 0.010 |
Why?
|
Libido | 1 | 1982 | 119 | 0.010 |
Why?
|
Child, Preschool | 4 | 2011 | 42230 | 0.010 |
Why?
|
Carcinogens | 1 | 1984 | 452 | 0.010 |
Why?
|
Smoking | 1 | 1998 | 9053 | 0.010 |
Why?
|
Classification | 1 | 2002 | 127 | 0.010 |
Why?
|
Thyroid Gland | 1 | 1988 | 1169 | 0.010 |
Why?
|
Epidermal Growth Factor | 1 | 1984 | 702 | 0.010 |
Why?
|
Extracellular Matrix | 1 | 2008 | 1726 | 0.010 |
Why?
|
Cisplatin | 2 | 1999 | 1652 | 0.010 |
Why?
|
Bacteriuria | 1 | 2000 | 102 | 0.010 |
Why?
|
T-Lymphocytes | 1 | 1997 | 10194 | 0.010 |
Why?
|
Crohn Disease | 1 | 1992 | 2279 | 0.010 |
Why?
|
Infant | 3 | 2011 | 36192 | 0.010 |
Why?
|
DNA Mutational Analysis | 1 | 2008 | 4111 | 0.010 |
Why?
|
Skin Neoplasms | 1 | 1999 | 5821 | 0.010 |
Why?
|
Whole-Body Irradiation | 1 | 2000 | 433 | 0.010 |
Why?
|
Urine | 1 | 2000 | 362 | 0.010 |
Why?
|
Lymph Nodes | 3 | 1997 | 3466 | 0.010 |
Why?
|
Chromosome Aberrations | 2 | 1997 | 1768 | 0.010 |
Why?
|
Analysis of Variance | 2 | 2001 | 6228 | 0.010 |
Why?
|
Neovascularization, Pathologic | 1 | 2008 | 2644 | 0.010 |
Why?
|
Prednisolone | 1 | 1999 | 326 | 0.010 |
Why?
|
Thyroid Neoplasms | 1 | 1991 | 2332 | 0.010 |
Why?
|
Trisomy | 1 | 1999 | 260 | 0.010 |
Why?
|
Chimera | 1 | 1999 | 453 | 0.010 |
Why?
|
Blood Grouping and Crossmatching | 1 | 1998 | 100 | 0.010 |
Why?
|
Papillary Muscles | 1 | 1978 | 192 | 0.010 |
Why?
|
Hypothyroidism | 1 | 1982 | 668 | 0.010 |
Why?
|
Platelet Transfusion | 1 | 2000 | 298 | 0.010 |
Why?
|
Mitotic Index | 1 | 1997 | 162 | 0.010 |
Why?
|
Antigens, CD20 | 1 | 1997 | 200 | 0.010 |
Why?
|
bcl-2-Associated X Protein | 1 | 1997 | 282 | 0.010 |
Why?
|
Proto-Oncogenes | 1 | 1997 | 321 | 0.010 |
Why?
|
Infertility | 1 | 1982 | 654 | 0.010 |
Why?
|
Radiation Injuries | 1 | 1982 | 1189 | 0.010 |
Why?
|
Receptors, Cell Surface | 1 | 1984 | 2822 | 0.010 |
Why?
|
Neoplasm Metastasis | 1 | 1985 | 4915 | 0.010 |
Why?
|
Menopause | 1 | 1982 | 1646 | 0.010 |
Why?
|
Chromosome Disorders | 1 | 1997 | 497 | 0.010 |
Why?
|
Safety | 1 | 1999 | 1150 | 0.010 |
Why?
|
Epirubicin | 1 | 1993 | 81 | 0.010 |
Why?
|
Graft vs Host Reaction | 1 | 1993 | 102 | 0.010 |
Why?
|
Antibodies, Viral | 1 | 1985 | 3156 | 0.010 |
Why?
|
Animals | 3 | 2020 | 168467 | 0.010 |
Why?
|
Antibiotics, Antineoplastic | 1 | 1997 | 678 | 0.010 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 1997 | 617 | 0.010 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 1997 | 621 | 0.010 |
Why?
|
Hydrocortisone | 1 | 2001 | 1819 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2008 | 8552 | 0.010 |
Why?
|
Chromosomes, Human, Pair 20 | 1 | 1992 | 127 | 0.010 |
Why?
|
Busulfan | 1 | 1993 | 258 | 0.010 |
Why?
|
B-Lymphocytes | 1 | 1985 | 4758 | 0.010 |
Why?
|
Melphalan | 1 | 1993 | 420 | 0.010 |
Why?
|
Cytarabine | 1 | 1993 | 698 | 0.010 |
Why?
|
Apolipoproteins B | 1 | 1991 | 386 | 0.010 |
Why?
|
Hypertension | 1 | 2009 | 8540 | 0.010 |
Why?
|
Tissue Donors | 1 | 1999 | 2332 | 0.010 |
Why?
|
Graft Survival | 1 | 2000 | 3820 | 0.010 |
Why?
|
Immunotherapy, Adoptive | 1 | 1999 | 1469 | 0.010 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 1997 | 1520 | 0.000 |
Why?
|
Radiography | 1 | 1999 | 6965 | 0.000 |
Why?
|
Probability | 1 | 1993 | 2477 | 0.000 |
Why?
|
Periodicals as Topic | 1 | 1979 | 1463 | 0.000 |
Why?
|
Cell Transformation, Neoplastic | 1 | 1997 | 2827 | 0.000 |
Why?
|
Radioimmunoassay | 1 | 1988 | 861 | 0.000 |
Why?
|
Stem Cells | 1 | 2000 | 3523 | 0.000 |
Why?
|
Immunosuppressive Agents | 1 | 2000 | 4176 | 0.000 |
Why?
|
Rats, Inbred Strains | 1 | 1988 | 2088 | 0.000 |
Why?
|
Insulin | 1 | 2001 | 6597 | 0.000 |
Why?
|
Ovarian Neoplasms | 1 | 1983 | 4878 | 0.000 |
Why?
|
Hemoglobins | 1 | 1991 | 1526 | 0.000 |
Why?
|
Immunoglobulin D | 1 | 1985 | 54 | 0.000 |
Why?
|
Immunochemistry | 1 | 1985 | 116 | 0.000 |
Why?
|
Dexamethasone | 1 | 1993 | 1948 | 0.000 |
Why?
|
Immunoglobulin lambda-Chains | 1 | 1985 | 82 | 0.000 |
Why?
|
Echocardiography | 1 | 1978 | 4989 | 0.000 |
Why?
|
Kidney Transplantation | 1 | 2000 | 4235 | 0.000 |
Why?
|
Regional Blood Flow | 1 | 1988 | 1496 | 0.000 |
Why?
|
Antibodies | 1 | 1991 | 2418 | 0.000 |
Why?
|
Genotype | 1 | 1997 | 12990 | 0.000 |
Why?
|
Dose-Response Relationship, Immunologic | 1 | 1983 | 364 | 0.000 |
Why?
|
Immunoenzyme Techniques | 1 | 1985 | 1705 | 0.000 |
Why?
|
Tyrosine | 1 | 1984 | 1440 | 0.000 |
Why?
|
Protein Kinase C | 1 | 1984 | 1202 | 0.000 |
Why?
|
Cross-Sectional Studies | 1 | 1999 | 26127 | 0.000 |
Why?
|
Amino Acids | 1 | 1984 | 1718 | 0.000 |
Why?
|
Heart Murmurs | 1 | 1978 | 92 | 0.000 |
Why?
|
Rupture, Spontaneous | 1 | 1978 | 362 | 0.000 |
Why?
|
Protein Kinases | 1 | 1984 | 1608 | 0.000 |
Why?
|
Uremia | 1 | 1978 | 201 | 0.000 |
Why?
|
Kinetics | 1 | 1984 | 6374 | 0.000 |
Why?
|
Cell Nucleus | 1 | 1985 | 2910 | 0.000 |
Why?
|
Breast Neoplasms | 1 | 1983 | 21017 | 0.000 |
Why?
|
Killer Cells, Natural | 1 | 1983 | 2201 | 0.000 |
Why?
|
Phosphorylation | 1 | 1984 | 8321 | 0.000 |
Why?
|
Rats | 1 | 1988 | 23741 | 0.000 |
Why?
|
Cell Line | 1 | 1984 | 15601 | 0.000 |
Why?
|
Heart Valve Prosthesis | 1 | 1978 | 1462 | 0.000 |
Why?
|
Carcinoma, Squamous Cell | 1 | 1984 | 4026 | 0.000 |
Why?
|
Mitral Valve Insufficiency | 1 | 1978 | 1400 | 0.000 |
Why?
|